AR074483A1 - Composiciones, metodos y usos para inducir al crecimiento viral - Google Patents

Composiciones, metodos y usos para inducir al crecimiento viral

Info

Publication number
AR074483A1
AR074483A1 ARP090104712A ARP090104712A AR074483A1 AR 074483 A1 AR074483 A1 AR 074483A1 AR P090104712 A ARP090104712 A AR P090104712A AR P090104712 A ARP090104712 A AR P090104712A AR 074483 A1 AR074483 A1 AR 074483A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
induce
growth
viral growth
Prior art date
Application number
ARP090104712A
Other languages
English (en)
Inventor
O'neil Wiggan
Jill A Livengood
Dan T Stinchcomb
Jorge Osorio
Original Assignee
Inviragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inviragen Inc filed Critical Inviragen Inc
Publication of AR074483A1 publication Critical patent/AR074483A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Las formas de realización de la presente informan acerca de métodos, composiciones y usos para inducir y/o acelerar el crecimiento de virus. En ciertas formas de realización, los métodos, composiciones y usos por lo general se relacionan con composiciones de copolímeros para inducir el crecimiento de virus, reducir el tiempo de retraso y/o incrementar el tamano de placa viral. En otras formas de realización, los métodos, composiciones y usos de composiciones de copolímeros pueden ser para inducir el crecimiento de flavivirus, reducir su retraso de crecimiento y/o incrementar su tamano de placa.
ARP090104712A 2008-12-05 2009-12-04 Composiciones, metodos y usos para inducir al crecimiento viral AR074483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12026208P 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
AR074483A1 true AR074483A1 (es) 2011-01-19

Family

ID=42231513

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104712A AR074483A1 (es) 2008-12-05 2009-12-04 Composiciones, metodos y usos para inducir al crecimiento viral

Country Status (20)

Country Link
US (3) US8871487B2 (es)
EP (1) EP2366024B1 (es)
JP (2) JP5728742B2 (es)
KR (1) KR101784951B1 (es)
CN (2) CN102272294B (es)
AR (1) AR074483A1 (es)
AU (1) AU2009322175B2 (es)
BR (2) BR122020015754B8 (es)
CA (1) CA2745962C (es)
CO (1) CO6390063A2 (es)
CU (1) CU20110128A7 (es)
HR (1) HRP20191324T1 (es)
IL (2) IL213389B (es)
MX (2) MX2011005886A (es)
MY (1) MY178195A (es)
NZ (1) NZ593415A (es)
SG (3) SG10201503671TA (es)
TW (2) TWI461536B (es)
WO (1) WO2010065911A1 (es)
ZA (2) ZA201104364B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272294B (zh) * 2008-12-05 2015-09-02 伊维拉根公司 用于诱导病毒生长的组合物、方法和用途
EP2746386A1 (en) * 2012-12-21 2014-06-25 Lonza Cologne GmbH Materials and methods for cell culture
WO2016159179A1 (ja) * 2015-03-30 2016-10-06 味の素株式会社 ヒト血清アルブミンを含む神経幹細胞増殖培地
WO2023147337A2 (en) * 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2024118740A1 (en) * 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
WO1998008934A1 (en) * 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CA2382919C (en) 1999-10-08 2008-12-09 Gruenenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives
ES2374131T3 (es) * 2000-02-16 2012-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus quiméricos avirulentos e inmunógenos.
WO2003060088A2 (en) * 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
US20050118701A1 (en) * 2002-03-29 2005-06-02 Weichang Zhou Large scale methods of producing adenovirus and adenovirus seed stocks
RU2237065C2 (ru) 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
PL199642B1 (pl) * 2002-11-15 2008-10-31 Inst Immunologii I Terapii Do Preparat bakteriofagowy o podwyższonej trwałości oraz zastosowanie blokowego kopolimeru tlenku etylenu i tlenku propylenu
WO2008041953A2 (en) * 2006-10-05 2008-04-10 Agency For Science, Technology And Research Dengue diagnosis and treatment
MY180465A (en) * 2007-04-06 2020-11-30 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
US8367370B2 (en) * 2008-02-11 2013-02-05 Wheeler Aaron R Droplet-based cell culture and cell assays using digital microfluidics
CN102272294B (zh) 2008-12-05 2015-09-02 伊维拉根公司 用于诱导病毒生长的组合物、方法和用途

Also Published As

Publication number Publication date
JP2012510822A (ja) 2012-05-17
BRPI0922788B8 (pt) 2021-05-25
CN102272294B (zh) 2015-09-02
JP2015109874A (ja) 2015-06-18
BRPI0922788B1 (pt) 2021-03-23
CN105219734B (zh) 2020-03-03
TWI573874B (zh) 2017-03-11
BR122020015754B8 (pt) 2021-04-06
IL213389A0 (en) 2011-07-31
BR122020015754B1 (pt) 2021-03-23
TWI461536B (zh) 2014-11-21
SG10202007719TA (en) 2020-09-29
EP2366024B1 (en) 2019-05-01
IL238819A (en) 2017-08-31
US9890362B2 (en) 2018-02-13
CA2745962C (en) 2018-11-27
WO2010065911A1 (en) 2010-06-10
IL213389B (en) 2018-10-31
CO6390063A2 (es) 2012-02-29
TW201030148A (en) 2010-08-16
MX2011005886A (es) 2011-07-28
MY178195A (en) 2020-10-06
US20100144015A1 (en) 2010-06-10
AU2009322175A1 (en) 2011-06-30
EP2366024A4 (en) 2012-07-04
HRP20191324T1 (hr) 2019-10-18
BRPI0922788A8 (pt) 2017-12-12
AU2009322175B2 (en) 2014-10-09
CA2745962A1 (en) 2010-06-10
ZA201600550B (en) 2021-08-25
EP2366024A1 (en) 2011-09-21
CU20110128A7 (es) 2012-06-21
NZ593415A (en) 2014-04-30
US20180251737A1 (en) 2018-09-06
KR20110127117A (ko) 2011-11-24
MX353602B (es) 2018-01-19
SG171972A1 (en) 2011-07-28
IL238819A0 (en) 2015-06-30
BRPI0922788A2 (pt) 2015-08-18
US20150010983A1 (en) 2015-01-08
CN105219734A (zh) 2016-01-06
ZA201104364B (en) 2022-10-26
KR101784951B1 (ko) 2017-10-12
CN102272294A (zh) 2011-12-07
JP5728742B2 (ja) 2015-06-03
SG10201503671TA (en) 2015-06-29
TW201514302A (zh) 2015-04-16
US8871487B2 (en) 2014-10-28
JP6174066B2 (ja) 2017-08-02

Similar Documents

Publication Publication Date Title
UY35131A (es) Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4
ECSP17064986A (es) Compuestos antivirales
CR20110453A (es) Combinación de un inhibidor de nucléosido polimerasa con un inhibidor de proteasa macrocíclica y su uso en el tratamiento de hepatitis c, fibrosis hepática y función hepática alterada
UY35266A (es) Compuestos antivirales
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
ECSP14013315A (es) Inhibidores de aplicación viral
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
CL2008000321A1 (es) Compuesto macrociclo en forma cristalina, inhibidor del virus de la hepatitis c (vhc); mezcla de una o mas formas cristalinas; procesos de preparacion de las formas cristalinas; y composicion farmaceutica que las comprende.
AR065984A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. composiciones farmaceuticas.
AR058215A1 (es) Metodos y proteinas para el tratamiento profilactico y o terapeutico de los cuatro serotipos del virus de dengue y otros flavivirus
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
ECSP10010002A (es) Derivados indólicos 2,3 sustituidos y métodos de uso de los mismos
BR112014006324B8 (pt) composição e seu uso para o tratamento de hcv
CO6541585A2 (es) Composiciones de lipopétidos y métodos relacionados
ECSP099447A (es) Derivados indólicos con anillo unido en las posiciones 4,5 y sus métodos de uso
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
AR074483A1 (es) Composiciones, metodos y usos para inducir al crecimiento viral
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
SV2011003796A (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
EA201290373A1 (ru) Синергическая противовирусная композиция и ее применение

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FG Grant, registration